/home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153
">
Warning: Undefined array key 0 in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153
Warning: Attempt to read property "cat_name" on null in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153
First Quarter 2019 Results Announced by Reading International
Earnings Call Webcast to Discuss 2019 First Quarter Financial Results
Scheduled to Post to Corporate Website on Tuesday, May 14, 2019
CULVER CITY, Calif.–(BUSINESS WIRE)–Reading International, Inc. (NASDAQ: RDI) today announced results for
the first quarter ended March 31, 2019. Our Company reported Basic
Earnings (Loss) per Share (“EPS”) of $(0.09), for the quarter ended
March 31, 2019 compared to an EPS of $0.13 for the same period in the
prior year, which was primarily driven by a weaker film slate in the
first quarter compared to the same period last year. The success of
films such as “Black Panther,” “Jumanji: Welcome to the Jungle,” and
“The Greatest Showman” during the first quarter of 2018 was not
repeated by the films offered in the first quarter of 2019. Cinema
segment revenues for the first three months of 2019 decreased by 20%, or
$14.3 million, to $58.0 million, compared to $72.3 million for the first
three months of 2018. We believe that our cinema results for the quarter
were similarly impacted as those of our competitors.
On the real estate front, our signature U.S. redevelopment project – the
historic Tammany Hall at 44 Union Square in Manhattan nears completion.
While no assurances can be given, we are in lease negotiations with a
credit tenant with respect to approximately 90% of the net rentable area
of the project. The prospective tenant has begun preparation of drawings
for the fit-out of the space and we have reached an agreement in
principle with respect to the key economic points. Drafts of the lease
have been exchanged. We anticipate that the project will be ready for
the commencement of tenant improvement work this quarter.
Ellen Cotter, Chair, President and Chief Executive Officer, said, “We
anticipated that when compared to the first quarter of 2018 the Black
Panther box office would be tough to match. However, the recent
blockbuster success of Avengers: Endgame again re-affirms our
confidence in the cinema industry and we look forward to that box office
momentum continuing through 2019.
“Also, we are pleased with the progress we have made on our 44 Union
Square project – the historic Tammany Hall in New York City and believe
this signature project, when completed, will unlock the long term value
in this one-time theatre property.”
Consolidated revenue for the first quarter of 2019 decreased by 19%, or
$14.3 million, to $61.6 million compared to the first quarter of 2018,
primarily due to a decreased attendance resulting from the weaker film
slate. These results were additionally negatively impacted by a
9.4% decline in the Australian dollar and a 6.3% decline in the New
Zealand dollar for the quarter ended March 31, 2019, compared to the
quarter ended March 31, 2018. Our New Zealand results were also
negatively impacted by the closure, due to seismic concerns, of our
Courtenay Central cinema in Wellington, which has historically been our
top performer in New Zealand.
The following table summarizes the first quarter results for 2019 and
2018:
Three Months Ended | ||||||||||||||||||||||
March 31, |
% Change Favorable/ |
|||||||||||||||||||||
(Dollars in millions, except EPS) | 2019 | 2018 | (Unfavorable) | |||||||||||||||||||
Revenue | $ | 61.6 | $ | 75.9 | (19 | ) | % | |||||||||||||||
– US | 33.1 | 38.7 | (14 | ) | % | |||||||||||||||||
– Australia | 23.8 | 29.1 | (18 | ) | % | |||||||||||||||||
– New Zealand | 4.7 | 8.1 | (42 | ) | % | |||||||||||||||||
Operating expense | $ | (62.9 | ) | $ | (70.2 | ) | (10 | ) | % | |||||||||||||
Segment operating income (1) | $ | 3.8 | $ | 12.0 | (68 | ) | % | |||||||||||||||
Net income/(loss) (2) |
$ | (2.1 | ) | $ | 3.1 | (168 | ) | % | ||||||||||||||
EBITDA (1) | $ | 4.3 | $ | 11.1 | (61 | ) | % | |||||||||||||||
Adjusted EBITDA (1) | $ | 4.8 | $ | 12.5 | (62 | ) | % | |||||||||||||||
Basic EPS (2) | $ | (0.09 | ) | $ | 0.13 | (169 | ) | % | ||||||||||||||
(1) |
Aggregate segment operating income, earnings before interest |
||
(2) |
Reflect amounts attributable to stockholders of Reading |
||
COMPANY HIGHLIGHTS
-
Operating Results: For
the quarter ended March 31, 2019, we had worldwide revenue of
$61.6 million, down $14.3 million from the prior year. Our operating
results were negatively impacted by (i) a weaker film slate worldwide,
(ii) a weaker film slate from the specialty distribution companies in
the U.S., and (iii) the closure of a majority of the net rentable area
of Courtenay Central, including our Reading Cinema at that location,
due to seismic concerns. -
Capex program: During
the first quarter of 2019, we invested $11.4 million in capital
improvements, including our continued investment in the redevelopment
of Tammany Hall, the upgrading of our multiplex cinemas (Harbour Town
in Australia and Mililani in the U.S.) and the lease acquisition of an
existing cinema in Devonport, Tasmania. -
Cinema Additions and Pipeline:
In early 2019, we purchased a well-established four-screen
cinema in Devonport, Tasmania. This lease acquisition brings our
global cinema count to 60 and our global screen count to 484. In
addition, we currently have signed lease agreements for four new
cinemas in Australia representing an additional 25 screens, which we
anticipate opening between 2019 and 2021. -
Building new revenue sources:
We continue to focus on the development of our self-ticketing
capabilities. We achieved a first quarter record for U.S. online
revenue, beating the prior year first quarter record by 14%. Online
sales consisted of 25% of our global box office revenue, which is a
first quarter record and represents an 18% increase from the prior
year period. Our continued improvements to our websites and apps in
the U.S. and improved global online sales infrastructure are enabling
us to better serve high sales volume.
Real estate activities:
-
44 Union Square Redevelopment (New York, U.S.)
– Our signature U.S. redevelopment project – the historic Tammany Hall
at 44 Union Square in Manhattan – is nearing completion. While
no assurances can be given, we are in negotiations on a lease with a
credit tenant for approximately 90% of the net rentable area of the
project. We anticipate that our project will be ready for the
commencement of tenant improvement work this quarter. -
Minetta Lane Theatre (New York, U.S.)
– In April, we negotiated an extension through March 2020 (with an
option to extend for an additional year through March 2021) of our
Minetta Lane Theatre license agreement with Audible, Inc., a
subsidiary of Amazon. Audible will continue to use our theatre as the
location for its production of various plays featuring one or two
actors, to be recorded before a live theatre audience, and offered on
Audible.com. -
Courtenay Central Redesign/Expansion
(Wellington, New Zealand) – Located in the heart of
Wellington – New Zealand’s capital city – this center is comprised of
161,071 square feet of land situated proximate to the Te Papa
Tongarewa Museum (attracting more than 1.5 million visitors annually),
across the street from the site of Wellington’s newly announced
convention center (estimated to open in 2022) and at a major public
transit hub. Damage from the 2016 earthquake necessitated demolition
of our nine-story parking garage at the site. Further, unrelated
seismic issues have caused us to close portions of the existing cinema
and retail structure while we reevaluate the property for
redevelopment as an entertainment themed urban center with a major
food and grocery component. Wellington continues to be rated as one of
the top cities in the world in which to live, and we continue to
believe that Courtenay Central is located in one of the most vibrant
and growing commercial and entertainment precincts of New Zealand.
SEGMENT RESULTS
The following table summarizes the first quarter segment operating
results for 2019 and 2018:
Three Months Ended | ||||||||||||||||||||||
March 31, |
% Change Favorable/ |
|||||||||||||||||||||
(Dollars in thousands) | 2019 | 2018 | (Unfavorable) | |||||||||||||||||||
Segment revenue | ||||||||||||||||||||||
Cinema |
||||||||||||||||||||||
United States | $ | 32,033 | $ | 37,987 | (16 | ) | % | |||||||||||||||
Australia | 21,441 | 26,717 | (20 | ) | % | |||||||||||||||||
New Zealand | 4,512 | 7,551 | (40 | ) | % | |||||||||||||||||
Total | $ | 57,986 | $ | 72,255 | (20 | ) | % | |||||||||||||||
Real estate |
||||||||||||||||||||||
United States | $ | 988 | $ | 655 | 51 | % | ||||||||||||||||
Australia | 3,916 | 4,154 | (6 | ) | % | |||||||||||||||||
New Zealand | 527 | 1,199 | (56 | ) | % | |||||||||||||||||
Total | $ | 5,431 | $ | 6,008 | (10 | ) | % | |||||||||||||||
Inter-segment elimination | (1,866 | ) | (2,391 | ) | 22 | % | ||||||||||||||||
Total segment revenue | $ | 61,551 | $ | 75,872 | (19 | ) | % | |||||||||||||||
Segment operating income | ||||||||||||||||||||||
Cinema |
||||||||||||||||||||||
United States | $ | (765 | ) | $ | 3,000 | (125 | ) | % | ||||||||||||||
Australia | 3,102 | 5,916 | (48 | ) | % | |||||||||||||||||
New Zealand | 305 | 1,369 | (78 | ) | % | |||||||||||||||||
Total | $ | 2,643 | $ | 10,285 | (74 | ) | % | |||||||||||||||
Real estate |
||||||||||||||||||||||
United States | $ | 27 | $ | (293 | ) | 109 | % | |||||||||||||||
Australia | 1,305 | 1,515 | (14 | ) | % | |||||||||||||||||
New Zealand | (174 | ) | 459 | (138 | ) | % | ||||||||||||||||
Total |
$ | 1,158 | $ | 1,681 | (31 | ) | % | |||||||||||||||
Total segment operating income (1) | $ | 3,801 | $ | 11,966 | (68 | ) | % | |||||||||||||||
“nm” – not meaningful for further analysis |
|||
(1) |
Aggregate segment operating income is a non-GAAP financial |
||
Consolidated and Non-Segment Results:
1st
Quarter Net Results
Compared to the quarter ended March 31, 2018, cinema segment operating
income decreased by 74%, or $7.6 million, to $2.6 million for the
quarter ended March 31, 2019, primarily driven by a decrease in
operating income in U.S., Australia, and New Zealand. The decrease was
due to a decrease in cinema attendance worldwide (principally due to a
weaker film slate), and fluctuations in average ticket price (“ATP”) and
spend per patron (“SPP”) as outlined below:
-
Revenue in the U.S. decreased by 16%, or $6.0 million, to
$32.0 million, due to a 22% decrease in attendance, offset partially
by a 12% increase in SPP and a 4% increase in ATP. -
Australia’s cinema revenue decreased by 20%, or $5.3 million, to $21.4
million primarily due to a 15% decrease in attendance, a 4% decrease
in ATP, and a decrease of 9% in SPP. -
New Zealand’s cinema revenue decreased by 40%, or $3.0 million versus
the same period in 2018. Attendance decreased by 40%, while ATP and
SPP percentages remained relatively flat compared to the same period
in the prior year. Not only did the weaker film slate from the major
studios impact our results, but our New Zealand cinema revenues were
also adversely impacted by the January 2019 closure of our Courtenay
Central cinema in Wellington due to seismic concerns.
The top three grossing films for the first quarter of 2019 were “Captain
Marvel,” “Aquaman,” and “How to Train Your Dragon: The
Hidden World,” representing approximately 29% of Reading’s worldwide
admission revenues for the quarter. The top three grossing films in the
first quarter of 2018 for Reading’s worldwide cinema circuits were “Black
Panther,” “Jumanji: Welcome to the Jungle,” and “The
Greatest Showman,” which represented approximately 32% of Reading’s
worldwide admission revenues for the quarter.
Real Estate
Segment Operating Income and Revenues:
Real estate segment operating income decreased by 31%, or $0.5 million,
to $1.2 million for the quarter ended March 31, 2019 compared to
March 31, 2018. For the quarter ended March 31, 2019, the real estate
segment revenue decreased by 10%, or $0.6 million, to $5.4 million,
compared to the same period in 2018. This was primarily attributable to
the closure due to seismic concerns of a majority of the net rentable
area of our Courtenay Central ETC during the first quarter of 2019,
compared to same period in 2018, which had a full quarter of operations,
offset by an increase in revenue at our Live Theatres.
CONSOLIDATED AND NON-SEGMENT RESULTS
The first quarter consolidated and non-segment results for 2019 and 2018
are summarized as follows:
Three Months Ended | ||||||||||||||||||||||||
March 31, |
% Change Favorable/ |
|||||||||||||||||||||||
(Dollars in thousands) | 2019 | 2018 | (Unfavorable) | |||||||||||||||||||||
Segment operating income | $ | 3,801 | $ | 11,966 | (68 | ) | % | |||||||||||||||||
Non-segment income and expenses: | ||||||||||||||||||||||||
General and administrative expense | (5,041 | ) | (6,156 | ) | 18 | % | ||||||||||||||||||
Interest expense, net | (1,852 | ) | (1,594 | ) | (16 | ) | % | |||||||||||||||||
Other | (47 | ) | 58 | 181 | % | |||||||||||||||||||
Total non-segment income and expenses | $ | (6,940 | ) | $ | (7,692 | ) | 10 | % | ||||||||||||||||
Income before income taxes | (3,139 | ) | 4,274 | 173 | % | |||||||||||||||||||
Income tax benefit (expense) | 1,042 | (1,170 | ) | 189 | % | |||||||||||||||||||
Net income/(loss) | $ | (2,097 | ) | $ | 3,104 | (168 | ) | % | ||||||||||||||||
Less: net income (loss) attributable to noncontrolling interests |
(16 | ) | 22 | nm | ||||||||||||||||||||
Net income (loss) attributable to RDI common stockholders |
$ | (2,081 | ) | $ | 3,082 | (168 | ) | % | ||||||||||||||||
“nm” – not meaningful for further analysis |
First Quarter Net Results
Net income attributable to RDI common stockholders was down $5.2 million
to a loss of $(2.1) million for the first quarter March 31, 2019,
compared to the same period prior year. Basic EPS for the quarter ended
March 31, 2019 decreased by $0.22 to a loss per share of $(0.09) from
the prior-year quarter, mainly attributable to a significant decrease in
revenue from both our Cinema and Real Estate business segments.
Non-Segment General & Administrative Expenses
Non-segment general and administrative expense for the quarter ended
March 31, 2019 compared to the same period of the prior year decreased
by 18%, or $1.1 million, to $5.0 million. The quarterly decrease mainly
relates to lower legal expenses for the quarter ending March 31, 2019 of
$1.0 million compared to the same period last year.
Income Tax Expense
Income tax expense for the quarter ended March 31, 2019, decreased 189%,
or $2.2 million, compared to the equivalent prior year period. The
change between 2019 and 2018 is primarily related to the pretax loss in
2019.
OTHER FINANCIAL INFORMATION
Balance Sheet and Liquidity
Total assets increased by $235.5 million, to $674.5 million at March 31,
2019, compared to $439.0 million at December 31, 2018. This was
primarily driven by the implementation of the lease accounting standards
effective January 1, 2019, which also resulted in a similar increase in
our liabilities. Additionally, assets increased due to the capital
investments relating to major real estate projects, primarily (i) the
redevelopment of our Union Square property in New York, and (ii)
improvements at our Mililani and Harbour Town cinemas. These were
partially offset by a reduction in our foreign-operation asset values
due to a decrease in the foreign exchange rates relative to the U.S.
dollar.
Cash and cash equivalents at March 31, 2019 were $12.6 million,
including approximately $8.8 million in the U.S., $3.2 million in
Australia, and $0.7 million in New Zealand. We manage our cash,
investments and capital structure so we are able to meet short-term and
long-term obligations for our business, while maintaining financial
flexibility and liquidity.
As part of our operating cycle, we utilize cash collected from (i) our
cinema business when selling tickets and F&B items, and (ii) rental
income typically received in advance, to reduce our long-term borrowings
and realize savings on interest charges. We then settle our operating
expenses generally with a lag within traditional trade terms. This
generates a temporary working capital deficit. We review the maturities
of our borrowings and negotiate for renewals and extensions, as
necessary for liquidity purposes. We believe the cash flow generated
from our operations coupled with our ability to renew and extend our
credit facilities will provide sufficient liquidity in the upcoming year.
OTHER INFORMATION
Our Stock Repurchase Program that expired on March 2, 2019, has been
extended by our Board of Directors through March 2, 2021. $16.2 million
remains available under that extended program. This will allow Reading
to repurchase its Class A Common Stock from time to time in accordance
with the requirements of the Securities and Exchange Commission on the
open market, in block trades and in privately negotiated transactions,
depending on market conditions and other factors.
On March 14, 2019, our Board of Directors approved the Company’s
three-year Strategic Plan to focus across the U.S., Australia, and New
Zealand on the upgrading of our existing cinemas to add luxury recliner
seating, TITAN branded auditoriums and enhanced F&B options, the
development in appropriate markets of new cinema opportunities, and the
continued development and/or redevelopment of our current real estate
assets.
After considering the approval of the Strategic Plan, our Board
concluded that the interests of our Company and our stockholders would
be best served by the continued pursuit of our Strategic Plan as an
independent company and that it had no interest in considering any sale
process at this time. Accordingly, we have advised Patton Vision that
our Board does not have any present interest in engaging in discussions
regarding their unsolicited indication of interest in the sale of our
Company. Our controlling stockholders are in agreement with this
approach.
In a matter potentially impacting the control of our company, but to
which our company is not a party (In re: James J. Cotter Living Trust
dated August 1, 2000 (Case No. BP159755) (the “Trust Case”)), the
California Court of Appeals on April 15, 2019, struck down the
California Trial Court’s order appointing a trustee ad litem to solicit
offers for the purchase of a controlling interest in our Company. The
basis for that disposition was the Appeals Court’s determination that
Mr. James J. Cotter, Jr., lacks standing to seek the appointment of such
a trustee ad litem. The Appeals Court noted that Mr. Cotter, Jr., is
neither a trustee of nor a beneficiary of the trust established to hold
such controlling interest (the “Voting Trust”) and accordingly,
determined that he lacked any standing to bring before the trial court
matters relating to the internal affairs of that trust, such as the
appointment of a trustee ad litem. The Court of Appeals also noted, in
an observation not material to the specific grounds on which the
California Trial Court’s order was struck down, but nevertheless likely
to be given weight by the court below, that “the plain language [of the
Trust Document] appears to show that the settlor [Mr. Cotter, Sr.]
instructed the Trustee [Margaret Cotter] not to diversify [i.e. not to
sell the voting shares held by the Voting Trust].” The Trust Document
directs the Trustee of the Voting Trust that this voting stock is “to be
retained for as long as possible.”
Ms. Margaret Cotter has advised the Board that she does not intend to
sell the controlling interest in our Company at this time, and that it
is her current intention that the Voting Trust hold such controlling
interest as provided in the Trust Document “as long as possible.”
We are informed that the Court of Appeal’s Order becomes final 30 days
after issuance.
The table below presents the changes in our working capital position and
other relevant information addressing our liquidity as of and for the
three months ended March 31, 2019 and preceding four years:
As of and for the 3-Months Ended |
Year Ended December 31 |
||||||||||||||||||||||||||||
($ in thousands) | 3/31/2019 | 2018 | 2017 | 2016 |
2015( (2)) |
||||||||||||||||||||||||
Total Resources (cash and borrowings) | |||||||||||||||||||||||||||||
Cash and cash equivalents (unrestricted) | $ | 12,648 | $ | 13,127 | $ | 13,668 | $ | 19,017 | $ | 19,702 | |||||||||||||||||||
Unused borrowing facility | 107,111 | 85,886 | 137,231 | 117,599 | 70,134 | ||||||||||||||||||||||||
Restricted for capital projects (1) | 23,566 | 30,318 | 62,280 | 62,024 | 10,263 | ||||||||||||||||||||||||
Unrestricted capacity | 83,545 | 55,568 | 74,951 | 55,575 | 59,871 | ||||||||||||||||||||||||
Total resources at period end | 119,759 | 99,013 | 150,899 | 136,616 | 89,836 | ||||||||||||||||||||||||
Total unrestricted resources at period end | 96,193 | 68,695 | 88,619 | 74,592 | 79,573 | ||||||||||||||||||||||||
Debt-to-Equity Ratio | |||||||||||||||||||||||||||||
Total contractual facility | $ | 290,879 | $ | 252,929 | $ | 271,732 | $ | 266,134 | $ | 207,075 | |||||||||||||||||||
Total debt (gross of deferred financing costs) | 184,099 | 167,043 | 134,501 | 148,535 | 130,941 | ||||||||||||||||||||||||
Current | 40,077 | 30,393 | 8,109 | 567 | 15,000 | ||||||||||||||||||||||||
Non-current | 143,691 | 136,650 | 126,392 | 147,968 | 115,941 | ||||||||||||||||||||||||
Finance lease liabilities | 331 | — | — | — | — | ||||||||||||||||||||||||
Total book equity(2) | 179,946 | 180,547 | 181,618 | 146,890 | 138,951 | ||||||||||||||||||||||||
Debt-to-equity ratio | 1.02 | 0.93 | 0.74 | 1.01 | 0.94 | ||||||||||||||||||||||||
Changes in Working Capital | |||||||||||||||||||||||||||||
Working capital (deficit) (3) | $ | (77,236 | ) | $ | (55,270 | ) | $ | (46,971 | ) | $ | 6,655 | $ | (35,581 | ) | |||||||||||||||
Current ratio | 0.28 | 0.35 | 0.42 | 1.10 | 0.51 | ||||||||||||||||||||||||
Capital Expenditures (including acquisitions) | $ | 11,476 | $ | 56,827 | $ | 76,708 | $ | 49,166 | $ | 53,119 | |||||||||||||||||||
(1) |
This relates to the construction facilities specifically negotiated for: (i) Union Square redevelopment project, obtained in December 2016, and (ii) New Zealand construction projects, obtained in May 2015. The New Zealand construction loan expired December 31, 2018. |
|||||||
(2) |
Certain 2015 balances included the restatement impact as a result |
|||||||
(3) |
Typically our working capital (deficit) is negative as we receive revenue from our cinema business ahead of the time that we have to pay our associated liabilities. We use the money we receive to pay down our borrowings in the first instance. |
|||||||
Below is a summary of the available credit facilities as of March 31,
2019:
As of March 31, 2019 | |||||||||||||||||||||||||
(Dollars in thousands) |
Available Contractual Capacity |
Capacity Used |
Unused Capacity |
Restricted for Capital Projects |
Unrestricted Capacity |
||||||||||||||||||||
Bank of America Credit Facility (USA) | $ | 55,000 | $ | 30,000 | $ | 25,000 | $ | — | $ | 25,000 | |||||||||||||||
Bank of America Line of Credit (USA) | 5,000 | 3,500 | 1,500 | — | 1,500 | ||||||||||||||||||||
Union Square Construction Financing (USA) | 57,500 | 33,934 | 23,566 | 23,566 | — | ||||||||||||||||||||
NAB Corporate Term Loan (AU) (1) | 85,248 | 40,138 | 45,110 | — | 45,110 | ||||||||||||||||||||
Westpac Bank Corporate (NZ) (1) | 21,824 | 9,889 | 11,935 | — | 11,935 | ||||||||||||||||||||
Total | $ | 224,572 | $ | 117,461 | $ | 107,111 | $ | 23,566 | $ | 83,545 |
(1) |
The borrowings are denominated in foreign currency. The |
|||||||
The $23.6 million representing borrowings restricted for capital
projects is wholly composed of the $23.6 million of unused capacity for
the Union Square development and construction.
Our overall global operating strategy is to conduct business mostly on a
self-funding basis by country (except for funds used to pay an
appropriate share of our U.S. corporate overhead). However, we may, from
time to time, move funds between jurisdictions where circumstances merit
such action as part of our goal to minimize our cost of capital.
Trust Preferred Securities – On October 11, 2018, Reading secured a
waiver that provides significant additional financial flexibility
through the elimination of financial covenants with respect to our Trust
Preferred Securities through the end of the term loan in consideration
of payments totaling $1.6 million, consisting of an initial payment of
$1.1 million paid on October 31, 2018, and a contractual obligation to
pay $270,000 in October 2021 and $225,000 in October 2025.
Minetta/Orpheum Loan – On October 12, 2018, the Minetta and Orpheum
Theatres loan of $7.5 million was increased to $8.0 million and the
maturity extended to November 1, 2023.
Non-GAAP Financial Measures
This earnings release presents aggregate segment operating income, and
EBITDA, which are important financial measures for the Company, but are
not financial measures defined by U.S. GAAP.
These measures should be reviewed in conjunction with the relevant U.S.
GAAP financial measures and are not presented as alternative measures of
EPS, cash flows or net income as determined in accordance with U.S.
GAAP. Aggregate segment operating income and EBITDA, as we have
calculated them, may not be comparable to similarly titled measures
reported by other companies.
Aggregate segment operating income – We evaluate the
performance of our business segments based on segment operating income,
and management uses aggregate segment operating income as a measure of
the performance of operating businesses separate from non-operating
factors.
Contacts
Gilbert Avanes, Interim Chief Financial Officer
Andrzej
Matyczynski, Executive Vice President for Global Operations
Reading
International, Inc.
(213) 235-2240
Warning: Undefined array key 0 in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 493
Warning: Attempt to read property "cat_ID" on null in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 493
Cannabis
Cannabis Capsule Global Analysis Report 2024: Market to Reach $79.2 Billion in 2028 – Forecast to 2033 Featuring GW Pharmaceuticals, Trulieve Cannabis, Green Thumb Industries, Tilray, Columbia Care
Innocan
Innocan Pharma Initiates FDA Approval Process for Liposome Injection Therapy for Chronic Pain
With its submission of a Pre-IND Meeting Request Letter, Innocan initiates the regulatory process with the U.S. Food and Drug Administration (FDA) for the approval of its prolonged CBD release technology for human use
HERZLIYA, Israel and CALGARY, AB, April 22, 2024 /PRNewswire/ — Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (“Innocan” or the “Company”), is pleased to announce that is has reached a key milestone: the Company submitted its letter of application for a Pre-IND meeting, the first phase in the FDA approval process in the United States for Innocan’s Liposome-Cannabidiol (LPT-CBD) injectable treatment of chronic pain.
With the global market for pain therapeutics widely expected to exceed US$100 billion by 2032[1], LPT therapy which requires only one single monthly subcutaneous injection, is positioned as a highly attractive alternative to opioid-based approaches. Opioids have and continue to take a significant human toll in recent years, with more than three-quarters of drug overdose deaths in the United States involving opioids, according to the United States Center for Disease Control and Prevention[2].
Innocan’s therapy has shown consistent efficacy in multiple pre-clinical trials in recent years of it’s LPT-CBD injectable treatment through prolonged and controlled release of CBD in animals with chronic pain conditions. Innocan’s Pre-IND Meeting Request Letter to the FDA is a key milestone and important first step in seeking approval of its LPT-CBD therapy for use in humans. At the Pre-IND meeting, the objective will be to obtain guidance from the FDA on the preclinical and clinical development plan, enabling the initiation of an Investigational New Drug (IND) program in the United States.
Iris Bincovich, CEO of Innocan, commented: “We are extremely excited to embark on this next stage in the development of LPT-CBD injectables, this is a major Milestone for Innocan Pharma. We have invested significant effort and many thousands of person-hours in its research and development, accumulating a wealth of preclinical data that will serve as the foundation for our participation in the FDA process. This is a key milestone for Innocan and marks our first step towards the FDA’s recognition of our technology. We see significant potential for our therapy, with an addressable market for pain management therapeutics expected to exceed US $100 billion by 2032, and we look forward to tapping that.“
Dr. Joseph Pergolizzi, Innocan’s FDA Advisory Board Member, added:
“We have worked hard to catalogue the data collected as part of our animal LPT therapy testing program and prepare it for the FDA. We look forward to working under FDA guidance, with the goal of completing the review process as quickly and efficiently as possible. We believe that Innocan’s unique treatment method, if and when it should become FDA-approved has the potential of being a highly valuable non-opioid addition in the medical arsenal of the management of chronic pain.”
About Innocan
Innocan is a pharmaceutical tech company that operates under two main segments: Pharmaceuticals and Consumer Wellness. In the Pharmaceuticals segment, Innocan focuses on developing innovative drug delivery platform technologies based on advanced cannabinoids science, to treat various conditions to improve patients’ quality of life. This segment involves two drug delivery technologies: (i) LPT CBD- loaded liposome platform facilitating exact dosing and the prolonged and controlled release of CBD into the blood stream. The LPT delivery platform research is in the preclinical trial phase for: Pain Management. In the Consumer Wellness segment, Innocan develops and markets a wide portfolio of innovative and high-performance self-care products to promote a healthier lifestyle. Under this segment, Innocan has established a joint venture by the name of BI Sky Global Ltd. that focuses on advanced targeted online sales. https://innocanpharma.com/
For further information, please contact:
For Innocan Pharma Corporation:
Iris Bincovich, CEO
+1-516-210-4025
+972-54-3012842
+442037699377
[email protected]
NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
Cautionary note regarding forward-looking information
Certain information set forth in this news release, including, without limitation, information regarding research and development, collaborations, the filing of potential applications with the FDA and other regulatory authorities, the potential achievement of future regulatory milestones, the potential for treatment of conditions and other therapeutic effects resulting from research activities and/or the Company’s products, requisite regulatory approvals and the timing for market entry, is forward-looking information within the meaning of applicable securities laws. By its nature, forward-looking information is subject to numerous risks and uncertainties, some of which are beyond Innocan’s control. The forward-looking information contained in this news release is based on certain key expectations and assumptions made by Innocan, including expectations and assumptions concerning the anticipated benefits of the products, satisfaction of regulatory requirements in various jurisdictions and satisfactory completion of requisite production and distribution arrangements.
Forward-looking information is subject to various risks and uncertainties which could cause actual results and experience to differ materially from the anticipated results or expectations expressed in this news release. The key risks and uncertainties include but are not limited to: general global and local (national) economic, market and business conditions; governmental and regulatory requirements and actions by governmental authorities; and relationships with suppliers, manufacturers, customers, business partners and competitors. There are also risks that are inherent in the nature of product distribution, including import / export matters and the failure to obtain any required regulatory and other approvals (or to do so in a timely manner) and availability in each market of product inputs and finished products. The anticipated timeline for entry to markets may change for a number of reasons, including the inability to secure necessary regulatory requirements, or the need for additional time to conclude and/or satisfy the manufacturing and distribution arrangements. As a result of the foregoing, readers should not place undue reliance on the forward-looking information contained in this news release concerning the timing of launch of product distribution. A comprehensive discussion of other risks that impact Innocan can also be found in Innocan’s public reports and filings which are available under Innocan’s profile at www.sedar.com.
Readers are cautioned that undue reliance should not be placed on forward-looking information as actual results may vary materially from the forward-looking information. Innocan does not undertake to update, correct or revise any forward looking information as a result of any new information, future events or otherwise, except as may be required by applicable law.
[1] https://www.gminsights.com/industry-analysis/pain-management-drugs-market
[2] https://www.cdc.gov/opioids/data/index.html
Logo – https://mma.prnewswire.com/media/2046271/3968398/Innocan_Pharma_Corporation_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/innocan-pharma-initiates-fda-approval-process-for-liposome-injection-therapy-for-chronic-pain-302122779.html
Curaleaf
Curaleaf Completes Acquisition of Northern Green Canada
Bolsters Company’s Advantage in Several Key Emerging Markets, including Australia, New Zealand, Germany, Poland and the United Kingdom
NEW YORK, April 22, 2024 /PRNewswire/ — Curaleaf Holdings, Inc. (TSX: CURA) (OTCQX: CURLF) (“Curaleaf” or the “Company”), a leading international provider of consumer cannabis products, announced today the closing of its acquisition of Northern Green Canada (“NGC”), a vertically integrated Canadian licensed cannabis producer focused primarily on expanding in the international market through its EU-GMP certification. The accretive acquisition amplifies the Company’s strategic advantage in established European markets including Germany, Poland and the United Kingdom and provides a foothold in the emerging markets of Australia and New Zealand.
Integrating NGC’s international operation will equip Curaleaf with a secure and consistent high quality, non-irradiated, indoor EU-GMP flower supply, essential to maintaining its leading positions in Germany, the United Kingdom and Poland.
“We are thrilled to welcome NGC formally to the Curaleaf family of global brands,” said Boris Jordan, Founder and Executive Chairman of Curaleaf. “This is an incredibly important deal for our international expansion strategy, as we’ll be able to bolster our supply of high quality EU-GMP certified flower immediately to key European markets as well as enter the fast-growing markets of Australia and New Zealand.”
The global cannabis market is projected to generate $55 billion in sales by 2027. Emerging markets beyond the United States and Canada, including Germany, Australia and New Zealand are expected to contribute $6.3 billion of the $55 billion projection.
Terms of the acquisition of NGC include an initial payment at closing of the Company’s Subordinate Voting Shares valued at approximately US $16 million, subject to a typical post-closing adjustment. An earnout may also be paid in 2025 based upon 2024 performance of NGC’s operations, up to 50% of which will be cash and the rest paid in additional Subordinate Voting Shares. The issuance of Subordinate Voting Shares in connection with the acquisition of NGC has been conditionally approved by the Toronto Stock Exchange, subject to fulfilling customary listing conditions.
About Curaleaf Holdings
Curaleaf Holdings, Inc. (TSX: CURA) (OTCQX: CURLF) (“Curaleaf”) is a leading international provider of consumer products in cannabis with a mission to enhance lives by cultivating, sharing and celebrating the power of the plant. As a high-growth cannabis company known for quality, expertise and reliability, the Company and its brands, including Curaleaf, Select, Grassroots, JAMS, Find and Zero Proof provide industry-leading service, product selection and accessibility across the medical and adult use markets. Curaleaf International is the largest vertically integrated cannabis company in Europe with a unique supply and distribution network throughout the European market, bringing together pioneering science and research with cutting-edge cultivation, extraction and production. Curaleaf is listed on the Toronto Stock Exchange under the symbol CURA and trades on the OTCQX market under the symbol CURLF. For more information, please visit https://ir.curaleaf.com.
Forward Looking Statements
This media advisory contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. These statements relate to future events or future performance. All statements other than statements of historical fact may be forward–looking statements or information. Generally, forward-looking statements and information may be identified by the use of forward-looking terminology such as “plans”, “expects” or, “proposed”, “is expected”, “intends”, “anticipates”, or “believes”, or variations of such words and phrases, or by the use of words or phrases which state that certain actions, events or results may, could, would, or might occur or be achieved. More particularly and without limitation, this news release contains forward-looking statements and information concerning the expected benefits of the acquisition of NGC, and the Company’s planned expansion on internal markets, the Company’s anticipated strategic advantages in European markets and emerging markets, the integration of NGC’s internal operations, the anticipated global cannabis market, and the listing of shares issuable in connection with the acquisition on the Toronto Stock Exchange. Such forward-looking statements and information reflect management’s current beliefs and are based on assumptions made by and information currently available to the Company with respect to the matters described in this new release, including the Company’s ability to successfully realize the expected benefits of the acquisition, and the Company’s ability to fulfil the listing conditions imposed by the Toronto Stock Exchange. Forward-looking statements involve risks and uncertainties, which are based on current expectations as of the date of this release and subject to known and unknown risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements, including the failure to realize the expected benefits of the acquisition, or the Company’s failure to fulfil the listing conditions imposed by the Toronto Stock Exchange. Additional information about these assumptions and risks and uncertainties is contained under “Risk Factors and Uncertainties” in the Company’s latest annual information form filed on March 6, 2024, which is available under the Company’s SEDAR profile at http://www.sedar.com, and in other filings that the Company has made and may make with applicable securities authorities in the future. Forward-looking statements contained herein are made only as to the date of this press release and we undertake no obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise, except as required by law. We caution investors not to place considerable reliance on the forward-looking statements contained in this press release. The Toronto Stock Exchange has not reviewed, approved or disapproved the content of this news release.
INVESTOR CONTACT
Curaleaf Holdings, Inc.
Camilo Lyon, Chief Investment Officer
[email protected]
MEDIA CONTACT
Curaleaf Holdings, Inc.
Tracy Brady, SVP Corporate Communications
[email protected]
View original content:https://www.prnewswire.co.uk/news-releases/curaleaf-completes-acquisition-of-northern-green-canada-302123010.html
-
Cannabis2 weeks ago
Hemp, Inc. Welcomes USDA Approval of GMO Hemp Strain – A Step Forward in Cannabis Biotechnology
-
Cannabis2 weeks ago
IM Cannabis and Flora Growth Partner to Bring Vessel Cannabis Accessories to the Israeli Market
-
Cannabis2 weeks ago
Right On Brands, Inc. Continues Rollout, Announces 13th Store Opening
-
Cannabis2 weeks ago
Avicanna Announces Completion of Topical Gel Observational Real-World Evidence Study
-
Cannabis2 weeks ago
Geopulse Exploration, Inc. Acquires 50% of ATC Services
-
Cannabis2 weeks ago
Tilray Brands, Inc. Reports Q3 Fiscal 2024 Financial Results
-
transfer1 week ago
IMC to transfer its Oranim Pharmacy shares back to the seller
-
Cannabis1 week ago
Right on Brands Announces Major Product Line Expansion via HONEY® Brands